Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

Virology Journal

Research

Jie Liu¹  Zhi Liu²  Zhenghua Ma³  Jingke Dong³  Xuejiao Liao³  Dapeng Li³  Dan Shu³  Xiangyi Yang³  Jing Yuan³  Lei Liu⁴  Zheng Zhang⁵ 

[1] Department of Neurology, Tianjin Medical University General Hospital, 300052, Tianjin, China;Department of the Third Pulmonary Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, 518112, Shenzhen, Guangdong Province, China;Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, 518112, Shenzhen, Guangdong Province, China;Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, 518112, Shenzhen, Guangdong Province, China;Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, 518112, Shenzhen, Guangdong Province, China;Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, 518112, Shenzhen, Guangdong Province, China;Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, 518112, Shenzhen, Guangdong Province, China;Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, 518112, Shenzhen, Guangdong Province, China;

关键词: COVID-19;    SARS-CoV-2;    Antibody therapy;    Delta variant;    Clinical manifestation;   

DOI  :  10.1186/s12985-022-01944-6

 received in 2022-04-25, accepted in 2022-12-02,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundClinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy.MethodsWe evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome.ResultsIn mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels.ConclusionThe results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12888_2022_4365_Article_IEq42.gif

12888_2022_4365_Article_IEq41.gif

Fig. 1

Fig. 5